Results 1 to 10 of about 1,579,650 (291)

PD-L1: expression regulation

open access: yesBlood Science, 2023
Programmed death-ligand 1 (PD-L1), expressed on the surface of tumor cells, can bind to programmed cell death-1 (PD-1) on T cells. The interaction of PD-1 and PD-L1 can inhibit T-cell responses by decreasing T-cell activity and accelerating their ...
Yu-Jie Zhou   +7 more
doaj   +3 more sources

Cuproptosis and Disulfidptosis Converge to Empower PD‐L1 Checkpoint Therapy via Cadict‐Induced PD‐L1 Translation [PDF]

open access: yesAdvanced Science
Immune checkpoint blockade (ICB) has emerged as a cornerstone of cancer therapy, yet its effectiveness remains restricted in PD‐L1‐low malignancies due to insufficient target expression.
Shaoqing Huang   +12 more
doaj   +2 more sources

Tumor cell PD-L1 predicts poor local control for rectal cancer patients following neoadjuvant radiotherapy

open access: yesCancer Management and Research, 2017
Lingdong Shao,* Qingqin Peng,* Kaixin Du,* Junyan He, Yaping Dong, Xiaoyi Lin, Jinluan Li, Junxin Wu Department of Radiation Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, People’s Republic of China *These ...
Shao LD   +7 more
doaj   +1 more source

Further investigation of blockade effects and binding affinities of selected natural compounds to immune checkpoint PD-1/PD-L1

open access: yesFrontiers in Oncology, 2022
The breakthrough in the discovery of immune checkpoint PD-1/PD-L1 inhibitors, such as the series of Bristol Myers Squibb synthetic compounds, boosted the research of small molecules with blockade effects on the interaction of PD-1/PD-L1.
Huifang Li   +3 more
doaj   +1 more source

PD-L1 [PDF]

open access: yesJournal of Clinical Pathology, 2017
Programmed death ligand 1 (PD-L1) is the principal ligand of programmed death 1 (PD-1), a coinhibitory receptor that can be constitutively expressed or induced in myeloid, lymphoid, normal epithelial cells and in cancer. Under physiological conditions, the PD-1/PD-L1 interaction is essential in the development of immune tolerance preventing excessive ...
Kythreotou A.   +4 more
openaire   +4 more sources

PD-1/PD-L1 blockade accelerates the progression of atherosclerosis in cancer patients

open access: yes, 2022
PD-1(programed death-1)/PD-L1(programed death-1 ligand) blockade represents a major breakthrough of anti-cancer therapies, however, it may come with increased risk of cardiovascular morbidity, such as myocarditis, acute coronary syndrome, arrhythmias ...
Tse, Gary   +8 more
core   +2 more sources

PD-L1 Amino Acid Position 88 Represents a Hotspot for PD-L1 Stability With Relevance for PD-L1 Inhibition

open access: yesFrontiers in Oncology, 2022
The two most common antibody targeting principles in oncology are the induction of direct antitumor effects and the release of antitumor T cell immunity by immune checkpoint blockade. These two principles, however, may be overlapping if the targeted checkpoint molecule is not located on the immune cell but on the tumor cell itself. Secondary resistance
Claaß, Luise V.   +7 more
openaire   +3 more sources

Role of regulation of PD-1 and PD-L1 expression in sepsis

open access: yesFrontiers in Immunology, 2023
Long term immunosuppression is problematic during sepsis. The PD-1 and PD-L1 immune checkpoint proteins have potent immunosuppressive functions. Recent studies have revealed several features of PD-1 and PD-L1 and their roles in sepsis. Here, we summarize
Teng Zhang, Li Yu-Jing, Tao Ma
doaj   +1 more source

PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential

open access: yesFrontiers in Immunology, 2020
PD-1/PD-L1 immune checkpoint inhibitors show potential for cervical cancer treatment. However, low response rates suggest that patient selection based on PD-L1 protein expression is not optimal.
Jossie Rotman   +13 more
doaj   +1 more source

PD-L1-Targeted Radionuclide Therapy Combined with αPD-L1 Antibody Immunotherapy Synergistically Improves the Antitumor Effect

open access: yes, 2022
Immune checkpoint blockers (ICBs) targeting programmed death receptor 1 (PD-1) ligand 1 (PD-L1) for immunotherapy have radically reformed oncology. It is of great significance to enhance the response rate of ICB in cancer patients. Here, a radioiodinated
Yiren Zhang (1760983)   +11 more
core   +1 more source

Home - About - Disclaimer - Privacy